7th RD20 Conference Gathers Global Researchers to Achieve Carbon Neutrality

22.9.2025 12:25:00 CEST | Business Wire | Press Release

The7th RD20 Conference, set for September 30 to October 3, 2025, will bring together Nobel Prize winner Dr. Akira Yoshino, world-leading researchers, and industry experts to accelerate R&D and international collaboration towards a carbon-neutral society. Hosted by the National Institute of Advanced Industrial Science and Technology (AIST), the event will feature cutting-edge presentations on technology development for sustainable synthetic fuels and renewable energy storage, and AI-powered clean energy solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250921861275/en/

A standout moment will be the Leaders Session on October 3, with a plenary lecture by Dr. Yoshino, a pioneering figure in lithium-ion batteries, who will discuss AIST’s Carbon Dioxide Removal technologies. Also presenting is Prof. Dr. Bernd Rech from Helmholtz-Zentrum Berlin für Materialien und Energie (HZB), who will introduce HZB’s green energy research and effective options for global partnerships.

This year’s conference will also showcase Taskforce Reports, focusing on urgent collaborative efforts to establish consistent Photovoltaic (PV) performance characterization techniques and advance hydrogen life-cycle sustainability assessments—key initiatives to achieve carbon neutrality.

The Technical Sessions (September 30 and October 1) will feature global experts discussing clean energy technologies:

Synthetic Fuels
Energy Storage for Renewables
AI and Digitalization for Energy Innovation

Event Outline

Dates: September 30 (Tue) – October 3 (Fri), 2025
Open Sessions: Sept. 30, Oct. 1 (Technical Sessions), Oct. 3 AM (Leaders Session)
Venue: Hotel Nikko Tsukuba & Online
Organizers: AIST, co-organized by METI, MEXT, MOE, and NEDO
Note: Officially certified as a “Theme Weeks Connect” program of Expo 2025 Osaka, Kansai

Details & Registration:https://rd20.aist.go.jp/conference/*Advanced registration is due on Friday, Sep. 26^th 9:00 JST

Media Accreditation (Media relations: Friday, Oct. 3, 12:05-12:35):https://forms.gzr.aist.go.jp/m?f=504

About RD20

Launched in 2019 under Japanese leadership, RD20 brings together leading research institutions from G20 nations to collaborate on cutting-edge technologies for a carbon-neutral future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250921861275/en/

Contacts

RD20 Secretariat, AIST
https://rd20.aist.go.jp/contact/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frd20.aist.go.j
p%2Fcontact%2F&esheet=54327270&newsitemid=20250921861275&lan=en-US&anchor=https%
3A%2F%2Frd20.aist.go.jp%2Fcontact%2F&index=3&md5=ad5a2c37299193e93dc2b896c9f839b
2
M-rd20secretariat-ml@aist.go.jp

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press Release

A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press Release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press Release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press Release

Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom